Customer stories.
We only publish case studies with written customer consent — never fabricated, never embellished.
Why nothing public yet?
Biopharma case studies require written customer consent, legal review, and disclosable data. Our standard is: customer reads the case study before we publish it.
- The customer has signed an MSA and used the platform for 3+ months.
- Written consent has been given to publish the case study and the quantified results.
- Legal has reviewed all data; nothing references unpublished IP.
- Quotes come from real emails or interviews — never written for marketing.
What you can read now
While we wait for the first published case study, you can evaluate inscinstech.ai with:
Design Partner Program
Before public case studies, we co-build with a small number of CMC teams. Design partners aren’t "early customers" — they help define the product.
Early access
New capabilities and skills reach you before general release; your feedback drives what we build next.
Shape the roadmap
Your real process pain points enter our iteration schedule — not an anonymous backlog.
Dedicated support
A direct engineering + CMC channel, not a ticket queue — someone answers the same day.
Co-authored case study
Once there are disclosable results, we write the case study together; you fully control the draft and what data is shared.
Already a customer? Apply for a case study.
If you already use inscinstech.ai and are willing to co-author a case study, our product marketing + BD team will pair with you. You control the draft.